Seattle, WA, United States of America

Lingfeng Liu

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 1.6

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Lingfeng Liu in Immunological Therapy

Introduction

Lingfeng Liu is a prominent inventor based in Seattle, WA, known for his significant contributions to immunological therapy. With a total of four patents to his name, Liu has been at the forefront of developing innovative solutions that enhance the efficacy of T cell therapies.

Latest Patents

Liu's latest patents include groundbreaking work on Universal T cells and methods for their use. This series of recombinant DNA constructs is designed for immunological therapy, particularly in disrupting T cell receptor (TCR), human leukocyte antigens (HLA) class I, and NKG2D ligand expression. The aim is to produce highly compatible autologous universal T cells that can be further genetically engineered for allogeneic administration. His Universal T (UT) construct comprises a TCR antibody fragment fused to a transmembrane domain and an ER retention domain of adenovirus early region 3 glycoprotein E3-19k. This construct can hijack ERAD machinery to arrest TCR and HLA molecules in the endoplasmic reticulum, facilitating their translocation into the cytoplasm for ubiquitination and degradation by proteasomes. Additionally, Liu has developed tagged chimeric effector molecules and receptor molecules for genetically engineering host cells, allowing for identification, isolation, sorting, and tracking of modified T cells for use in adoptive immunotherapy.

Career Highlights

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…